Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
